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Chronic lymphocytic leukemia (CLL) is a malignant disease characterized by the accumulation of mature CD5 þ B cells in the blood, bone marrow and secondary lymphoid organs. 1 Unlike most tumor entities, there is only a small proportion of CLL cells that proliferate. 2 This has led to the hypothesis that the accumulation of CLL cells in vivo is not due to increased proliferation rates, but rather due to resistance to apoptosis. 1 In CLL, resistance to apoptosis is supported by microenvironmental signals, as CLL cells cultured without support in vitro rapidly undergo apoptosis. In vitro, apoptosis of CLL cells can be prevented by co-culture with supporting cells, either indirectly through soluble factors and/or by direct interaction through cellsurface receptors. 3 From peripheral blood monocytes (PBMCs) of CLL patients, a subset of cells (CD14 þ cells) differentiate in vitro into large, round, adherent cells ('Nurse-like cells', NLCs) that assist in survival of CLL cells. 4 Cells that are morphologically and immunophenotypically similar to NLCs can also be differentiated from CD14
þ PBMCs of healthy donors by cultivating them in vitro with CLL cells. 5 In vivo, NLCs have been described to be present in the spleen and lymph nodes of CLL patients, suggesting that NLCs might promote survival of CLL cells also in these tissues. 5, 6 Several proteins that are involved in the pro-survival capabilities of NLCs have been identified: CXCL12, 4 CXCL13, 6 BAFF (B-cell activating factor of the tumor necrosis factor family), 7 APRIL (a proliferationinducing ligand) 7 and CD31 (PECAM1). 8 NLCs have an expression profile of surface and cytoplasmic antigens that is distinct from that of other cells of the myelo-monocytic lineage. 5 NLCs have a significantly higher CD68 expression compared with monocytes, macrophages and dendritic cells from healthy donors. 5 What remains unclear is whether the differentiation of NLCs is specific to CLL or whether non-malignant B cells can also convert CD14
þ PBMCs to cells with pro-survival capacities.
We -g ). We found that NLCs might indeed help in the survival of CLL cells in the lymph node as reported previously. 6 Interestingly, non-malignant tonsil and lymph node sections from healthy individuals were positive for these markers as well (Figures 1d and h ). Although it is known that NLCs have higher CD68 intensities than macrophages and dendritic cells, immunohistochemistry is not well suited for a quantitative analysis. Ideally, markers specific to NLCs will be required to make a definitive statement about the exclusive presence of NLCs in the lymphatic tissues of CLL. Nevertheless, our results give rise to the possibility that NLC-like cells are present in the lymphatic tissues of healthy individuals as well as CLL patients.
For functional analysis of a CLL-specific phenotype of NLCs, we generated these cells as previously described 5 (please refer to Figure 2a for a schematic of the experimental setup). Similar to NLCs, after culture, in vitro CD14 þ cells differentiated by CLL cells (CD14 CLL cells) as well as CD14 þ cells differentiated by non-malignant B cells (CD14 B cells) were positive for CD68, CD14 and negative for both CD1a (bloodderived dendritic cell marker) and CD15 (granulocyte marker) (data not shown).
One of the central phenotypic capabilities of NLCs is their potential to support survival of CLL cells. However, so far it is unclear whether this competence is specific for CLL or can also be induced in monocytes by non-malignant B cells. In order to test whether CD14 B cells are capable of supporting survival, longterm allogeneic co-cultures of either CLL cells or non-malignant B cells with CD14
þ PBMCs from healthy donors were initiated (Figure 2a) . After 18 days of co-culture, survival of suspension cells was compared between continued co-culture on differentiated adherent cells (NLCs, CD14 CLL cells and CD14 B cells) and culture of suspension cells with medium alone.
All cultures with medium alone led to significant loss of viability of suspension cells (34.6 ± 16.1% (without þ and CD14 þ cells are present in lymphatic tissues of CLL patients and healthy donors. Lymph node sections from CLL patients (n ¼ 4) were stained with anti-CD14 (cryosections) or anti-CD68 antibody (paraffin sections) (see Supplementary materials and methods for details). Shown are representative lymph node sections from patients stained with CD68 (a-c) and CD14 (e-g). The tonsil and lymph node sections from healthy donors were also positive for CD68 (d) and CD14 (h).
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NLCs), 45.6±13.8% (without CD14 CLL cells) and 23.1±5.83% (without CD14 B cells at day 9)). Survival rates of CLL cells replated on NLCs (n ¼ 3) or CD14 CLL cells (n ¼ 4) remained stable, with mean viabilities of 95.1 ± 1.8% (on NLCs) and 95.7±4.5% (on CD14 CLL cells) at day 9 compared with viability at day 0 (Figures 2b and c) . Interestingly, also CD14 B cells helped in the survival of non-malignant B cells (mean viability 90.2 ± 3.37% (on CD14 B cells) at day 9 compared with viability at day 0 (Figure 2d) ). This indicates that all three differentiated cell types have pro-survival capacities and that this competence is not only induced by the CLL setting.
Intrigued by our observation that CD14 B cells also possess pro-survival capability, we assessed expression levels of prosurvival genes in all three differentiated supporting cell types. Previous work demonstrated that expression of BAFF, APRIL and PECAM1 (CD31) by NLCs provides pro-survival support to CLL cells. In order to test whether these effects are specific to CLL, we quantified and compared the levels of BAFF, APRIL and PECAM1 mRNA (Figure 3) among NLCs, CD14 CLL and CD14 B cells. In line with the observed pro-survival capabilities, there were no significant differences in the gene expression levels of BAFF, APRIL and PECAM1 among NLCs, CD14 CLL and CD14 B cells, except for a single outlier (Figure 3b(i) ). The lack of different expression levels together with the enhanced prosurvival capacity induced by CLL cells and non-malignant B cells indicates that both CLL cells as well as non-malignant B cells can convert CD14 cells to cell types with pro-survival capacities, suggesting that this phenomenon might not be specific to CLL.
In a next step, we tested whether CD14 þ cells differentiated by CLL cells (CD14 CLL cells and NLCs, n ¼ 4 experiments each) as well as CD14 þ cells differentiated by non-malignant B cells (CD14 B cells, n ¼ 4 experiments) had a similar transcriptomewide expression of survival genes. We adopted a more comprehensive approach and compared the expression levels of all genes belonging to the GO category 'programmed cell death' (GO:0012501), which is attributed to 1143 genes. Of these genes, 1131 genes are represented by 1877 oligonucleotides on the Illumina Human Sentrix-12 BeadChip array. Genes differentially expressed between CD14 B cells and CD14 CLL cells/NLCs were identified by class comparison analyses using Biometric Research Branch (BRB) Array Tools software (BRB, National Cancer Institute, Bethesda, MD, USA). Only 129 of 1877 oligonucleotides (6.8%) representing 121 unique genes were differentially regulated between CD14 cells differentiated by CLL cells or by non-malignant B cells (univariate test Po0.05). Interestingly, only 15 out of these 121 genes had a deregulation greater than 1.5-fold between CD14 B cells and CD14 CLL cells/NLCs (Supplementary Table) . This means that merely 15/1131, that is 1.3% of all genes involved in programmed cell death, are differentially regulated (Po0.05 and fold change 41. Letters to the Editor non-malignant B cells have a very similar pro-survival capacity compared with their counterparts that are differentiated by CLL cells.
In conclusion, our findings suggest that (1) cells expressing markers known to be expressed by NLCs are present in the lymphatic tissues of CLL patients as well as healthy individuals, indicating that NLCs might not be specific to CLL. (2) In vitro, both CLL-B cells as well as non-malignant B cells can convert CD14 þ cells to cell types with pro-survival capacities. This is also reflected by similar RNA levels of survival genes previously reported to be expressed by NLCs. (3) Transcriptome-wide analysis of genes annotated with the GO term 'programmed cell death' revealed that merely 1.3% of these genes are differentially regulated between CD14 B cells and CD14 CLL cells/NLCs. These results suggest that both non-malignant B cells and CLL cells induce a similar pro-survival phenotype in CD14 þ cells from peripheral blood. It might have to be re-considered whether the pro-survival capacity of NLCs is specific to CLL patients. As mentioned earlier, a more detailed analysis of the phenotype of NLCs will be required to show the specificity of these cells to CLL patients. In addition, it will be interesting to investigate whether CLL cells induce in CD14 þ cells additional pathways not involved in survival, and whether these pathways are specific to CLL and cannot be induced by non-malignant B cells. . The data represent log(2) intensities of quantile-normalized signals of respective genes on the microarray (a) and log(2) expression of the respective mRNA normalized to two housekeeping genes (TBP and HMBS) used as internal controls (b). The median expression levels of the indicated genes were not significantly different (P ¼ n.s. indicates not significant, i.e., P40.05).

